Antiviral Activity of Lenacapavir Against Human Immunodeficiency Virus Type 2 (HIV-2) Isolates and Drug-Resistant HIV-2 Mutants
Robert A. Smith, Dana N. Raugi, Robert S. Nixon, Moussa Seydi, Nicolas Margot, Christian Callebaut, Geoffrey S. Gottlieb, Fatima Sall, Khardiata Diallo, Mouhamadou Baïla Diallo, Khadim Faye, Samba Cisse, Fatou Simal, Marie Pierre Sy, Binetou Diaw, Ousseynou Ndiaye, Babacar Faye, Ndeye Astou Diop, Amadou Bale Diop, Marianne Fadiome, ElHadji Ibrahima Sall, Boubacar Kande, Jean Jacques Malomar, Ousseynou Cisse, Ibrahima Tito Tamba, Dominique Faye, Papa Amadou Diallo, Mamadou Habib Diop, Jean Phillippe Diatta, Adji Fatoumata Diene, François Badiane, Baboucar Diatta, Raphael Bakhoum, Aïssatou Barry, Aissatou Mamy Sané, Jacques F. Sambou, Bokeni Diedhiou, Sidy Diatta, Juliette Gomis, Terese Dieye, Stephen E. Hawes, Noelle A. Benzekri, John Lin, Ming Chang, Robert Coombs, James I. Mullins, Papa Salif Sow, Nancy B. Kiviat
Abstract
The activity of lenacapavir against human immunodeficiency virus type 1 (HIV-1) has been extensively evaluated in vitro, but comparable data for human immunodeficiency virus type 2 (HIV-2) are scarce. We determined the anti-HIV-2 activity of lenacapavir using single-cycle infections of MAGIC-5A cells and multicycle infections of a T-cell line. Lenacapavir exhibited low-nanomolar activity against HIV-2, but was 11- to 14-fold less potent against HIV-2 in comparison to HIV-1. Mutations in HIV-2 that confer resistance to other antiretrovirals did not confer cross-resistance to lenacapavir. Although lenacapavir-containing regimens might be considered for appropriate patients with HIV-2, more frequent viral load and/or CD4 testing may be needed to assess clinical response.